

### **REMARKS/ARGUMENTS**

The Restriction action dated 2 August 2006 required election between claim groups I-III. Applicants herein elect claim group I, including claims 4-7, 13-16 and 20, and generic claims 1-3 and 10-12. Claims 3-5, 7-9, 12-15 and 17-19 are cancelled without prejudice or disclaimer.

Claim 1 is amended to incorporate the subject matter of cancelled claims 3-5. Claim 6 is amended to incorporate the subject matter of cancelled claim 7. Claim 10 is amended to incorporate the subject matter of cancelled claims 12-15. Claim 16 is amended to correct dependency. Claim 20 is amended as an independent claim which includes the language of cancelled claim 5 and claim 7. No new matter is added by this amendment.


### **Conclusion**

It is believed that this document is fully responsive to the Restriction requirement raised in the Restriction action dated 2 August 2006. In light of the above amendments and remarks, it is believed that the claims are now in condition for allowance, and such action is respectfully urged.

### **Fees**

It is believed that no fee is due with the submission of this response. In the event it is determined that a fee is due, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650 for the amount of that fee.

Respectfully submitted



Valeta Gregg, Ph.D., Reg. No. 35,127  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 593-1077 (direct)